InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,070.80
(
1.90%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.57
(
1.34%
)
Bitcoin
66,448.97
(
-0.61%
)
Post# of 251572
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119459
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 148813

Thursday, 10/04/2012 9:52:20 PM

Thursday, October 04, 2012 9:52:20 PM

Post# of 251572
Teva halts Rituxan FoB program:

http://www.haaretz.com/business/teva-halts-tests-of-cancer-drug-biosimilar.premium-1.468148

It’s unclear whether this was a technical decision or a business decision. It could well be the latter insofar as there are multiple companies vying for non-interchangeable Rituxan FoB’s, so the profit margins after sales and marketing costs would seem to be meager.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up